Abstract Number: 0545 • ACR Convergence 2021
SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells
Background/Purpose: Vascular abnormalities in systemic sclerosis (SSc) are characterized by injury to vascular wall and extensive damage of the microvessels. It has been shown that…Abstract Number: 0546 • ACR Convergence 2021
Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…Abstract Number: 0555 • ACR Convergence 2021
Pathway-Driven Drug Repositioning in Systemic Sclerosis from Omics Data
Background/Purpose: Omic analyses of systemic sclerosis (SSc) skin biopsy datasets identified distinct sets of patients that respond differently to treatment. The goal of this study…Abstract Number: 0557 • ACR Convergence 2021
The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway
Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…Abstract Number: 0966 • ACR Convergence 2021
Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis
Background/Purpose: Cutaneous lupus erythematosus (CLE) is commonly present in patients with systemic lupus erythematosus (SLE), but can also exist as an isolated manifestation without further…Abstract Number: 1437 • ACR Convergence 2021
Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis
Background/Purpose: Early loss of skin-associated adipose tissue and concomitant replacement by extracellular matrix is a hallmark of systemic sclerosis (SSc). However, the contribution of adipose…Abstract Number: 1491 • ACR Convergence 2021
Single-cell Analysis of Paired Skin and Blood Samples from Patients with SLE and Cutaneous Lupus Suggests CD16+ DCs Arise from Non-classical Monocytes That Enter Nonlesional Skin, Undergo Type I IFN Education, and Engage in Extensive Crosstalk with Diverse Immune and Stromal Cell Types
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an incompletely understood autoimmune disease that can occur in isolation or in the context of SLE. CLE is often…Abstract Number: 1495 • ACR Convergence 2021
Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials
Background/Purpose: Lupus erythematous (LE) is a systemic autoimmune disease with a variety of cutaneous manifestations. Antimalarials are first-line systemic therapy, yet not all patients respond…Abstract Number: 1759 • ACR Convergence 2021
An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients
Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…Abstract Number: 1784 • ACR Convergence 2021
Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry
Background/Purpose: Patients (pts) with mild to moderate psoriasis (PsO) and musculoskeletal disease burden may be diagnosed with PsA upon referral to a rheumatologist. Early intervention…Abstract Number: 1857 • ACR Convergence 2021
Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis
Background/Purpose: To assess skin involvement in a cohort of patients with systemic sclerosis (SSc) comparing results obtained from modified Rodnan skin score (mRSS), durometry and…Abstract Number: L09 • ACR Convergence 2020
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…Abstract Number: L10 • ACR Convergence 2020
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…Abstract Number: 0402 • ACR Convergence 2020
Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis
Background/Purpose: The Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) study has shown that more than 80% of patients with Raynaud’s Phenomenon, specific ANA positivity and…Abstract Number: 0512 • ACR Convergence 2020
Efficacy of Apremilast for the Treatment of Manifestations of Behçet’s Syndrome Other Than Oral Ulcers, Including Skin Lesions and Arthritis
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful and recurrent oral ulcers (OU) and other manifestations, such as skin lesions and…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- Next Page »